Saves everyone looking it up:
Further details on the Phase IIb trial design including the expected timing for trial application and approval for the Phase IIb trial of ATL1102 in non-ambulant DMD patients to be conducted in Europewill be communicated to the market once the final opinion is received from PDCO following their 15 October 2021 meeting.
Saves everyone looking it up: Further details on the Phase IIb...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 11000 | 1 |
View Market Depth
| Last trade - 10.19am 06/05/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable